A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy.
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Ramucirumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms REVEL
- Sponsors Eli Lilly
- 16 Oct 2017 Results of subgroup analysis presented at the 18th World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer, according to an Eli Lilly and Company media release.
- 16 Oct 2017 Results of subgroup analysis presented in an Eli Lilly and Company media release.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History